[EN] PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS DE PROTÉINE TYROSINE PHOSPHATASE ET LEURS PROCÉDÉS D'UTILISATION
申请人:CALICO LIFE SCIENCES LLC
公开号:WO2020186199A1
公开(公告)日:2020-09-17
Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases, disorders and conditions favorably responsive to PTPN 1 or PTPN2 inhibitor treatment, e.g., a cancer or a metabolic disease.
A cooperative catalytic system involving a Pd/XPhos complex and inexpensive 5-norbornene-2-carbonitrile that enables the use of alkyl tosylates as alkylating reagents in the Catellani reaction has been developed. This mild, scalable protocol is compatible with a range of readily available functionalized aryl iodides and alkyl tosylates, as well as terminating olefins (45 examples, up to 97% yield)
5-Alkyl-1,2,3,4-tetrahydroquinolines, New Membrane-Interacting Lipophilic Metabolites Produced by Combined Culture of <i>Streptomyces nigrescens</i> and <i>Tsukamurella pulmonis</i>
5-alkyl-1,2,3,4-tetrahydroquinolines (5aTHQs) bearing different side chains have been isolated from a combined culture of Streptomycesnigrescens HEK616 and Tsukamurellapulmonis TP-B0596. The chemical structures including the absolute configuration were elucidated by spectroscopic analysis and totalsynthesis. 5aTHQs inhibited the growth of wild-type fission yeast while only weakly inhibiting the growth
Protein tyrosine phosphatase inhibitors and methods of use thereof
申请人:Calico Life Sciences LLC
公开号:US10851073B2
公开(公告)日:2020-12-01
Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases, disorders and conditions favorably responsive to PTPN1 or PTPN2 inhibitor treatment, e.g., a cancer or a metabolic disease.